skip to main content
Guest
My Research
My Account
Sign out
Sign in
This feature requires javascript
Library Search
Find Databases
Browse Search
E-Journals A-Z
E-Books A-Z
Citation Linker
Help
Language:
English
Vietnamese
This feature required javascript
This feature requires javascript
Primo Search
All Library Resources
All
Course Materials
Course Materials
Search For:
Clear Search Box
Search in:
All Library Resources
Or hit Enter to replace search target
Or select another collection:
Search in:
All Library Resources
Search in:
Print Resources
Search in:
Digital Resources
Search in:
Online E-Resources
Advanced Search
Browse Search
This feature requires javascript
Search Limited to:
Search Limited to:
Resource type
criteria input
All items
Books
Articles
Images
Audio Visual
Maps
Graduate theses
Show Results with:
criteria input
that contain my query words
with my exact phrase
starts with
Show Results with:
Search type Index
criteria input
anywhere in the record
in the title
as author/creator
in subject
Full Text
ISBN
ISSN
TOC
Keyword
Field
Show Results with:
in the title
Show Results with:
anywhere in the record
in the title
as author/creator
in subject
Full Text
ISBN
ISSN
TOC
Keyword
Field
This feature requires javascript
Pancreatic cancer
The Lancet (British edition), 2020-06, Vol.395 (10242), p.2008-2020
[Peer Reviewed Journal]
2020 Elsevier Ltd ;2020. Elsevier Ltd ;ISSN: 0140-6736 ;EISSN: 1474-547X ;DOI: 10.1016/S0140-6736(20)30974-0
Full text available
Citations
Cited by
View Online
Details
Recommendations
Reviews
Times Cited
External Links
This feature requires javascript
Actions
Add to My Research
Remove from My Research
E-mail
Print
Permalink
Citation
EasyBib
EndNote
RefWorks
Delicious
Export RIS
Export BibTeX
This feature requires javascript
Title:
Pancreatic cancer
Author:
Mizrahi, Jonathan D
;
Surana, Rishi
;
Valle, Juan W
;
Shroff, Rachna T
Subjects:
5-Fluorouracil
;
Age
;
BRCA1 protein
;
Cancer
;
Cell cycle
;
Chemotherapy
;
Computed tomography
;
Cyclin-dependent kinases
;
Diabetes
;
Diabetes mellitus
;
Diabetes mellitus (non-insulin dependent)
;
Diagnostic systems
;
Endoscopes
;
Epidemiology
;
Family medical history
;
Folinic acid
;
Gemcitabine
;
Gene expression
;
Genetics
;
Health risk assessment
;
Health risks
;
Intravenous administration
;
Irinotecan
;
Kinases
;
Medical prognosis
;
Medical research
;
Medical treatment
;
Metastases
;
Mutation
;
Oxaliplatin
;
Paclitaxel
;
Pancreatic cancer
;
Pancreatitis
;
Poly(ADP-ribose) polymerase
;
Risk analysis
;
Risk factors
;
Signs and symptoms
;
Smoking
;
Survival
;
Tobacco
;
Tumors
;
Ultrasound
Is Part Of:
The Lancet (British edition), 2020-06, Vol.395 (10242), p.2008-2020
Description:
Pancreatic cancer is a highly fatal disease with a 5-year survival rate of approximately 10% in the USA, and it is becoming an increasingly common cause of cancer mortality. Risk factors for developing pancreatic cancer include family history, obesity, type 2 diabetes, and tobacco use. Patients typically present with advanced disease due to lack of or vague symptoms when the cancer is still localised. High quality computed tomography with intravenous contrast using a dual phase pancreatic protocol is typically the best method to detect a pancreatic tumour and to determine surgical resectability. Endoscopic ultrasound is an increasingly used complementary staging modality which also allows for diagnostic confirmation when combined with fine needle aspiration. Patients with pancreatic cancer are often divided into one of four categories based on extent of disease: resectable, borderline resectable, locally advanced, and metastatic; patient condition is also an important consideration. Surgical resection represents the only chance for cure, and advancements in adjuvant chemotherapy have improved long-term outcomes in these patients. Systemic chemotherapy combinations including FOLFIRINOX (5-fluorouracil, folinic acid [leucovorin], irinotecan, and oxaliplatin) and gemcitabine plus nab-paclitaxel remain the mainstay of treatment for patients with advanced disease. Data on the benefit of PARP inhibition as maintenance therapy in patients with germline BRCA1 or BRACA2 mutations might prove to be a harbinger of advancement in targeted therapy. Additional research efforts are focusing on modulating the pancreatic tumour microenvironment to enhance the efficacy of the immunotherapeutic strategies.
Publisher:
London: Elsevier Ltd
Language:
English
Identifier:
ISSN: 0140-6736
EISSN: 1474-547X
DOI: 10.1016/S0140-6736(20)30974-0
Source:
ProQuest One Psychology
ProQuest Central
This feature requires javascript
This feature requires javascript
Back to results list
This feature requires javascript
This feature requires javascript
Searching Remote Databases, Please Wait
Searching for
in
scope:(TDTS),scope:(SFX),scope:(TDT),scope:(SEN),primo_central_multiple_fe
Show me what you have so far
This feature requires javascript
This feature requires javascript